Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02779751 · ClinicalTrials.gov registry record · Phase 1
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT02779751 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 100 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT02779751, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Anastrozole
- DRUG Abemaciclib
Study Locations (20)
Other
- Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Leuven
- Centre Hospitalier Universitaire Sart Tilman - Liège
- Hopital Larrey - Toulouse
- IRCCS Ospedale San Raffaele - Milan
- Hospital Nuestra Senora de Sonsoles - Ávila
- Hospital San Pedro de Alcantara - Cáceres
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Madrid Norte Sanchinarro - Madrid
- Tri-Service General Hospital - Neihu Taipei
- Taipei Medical University- Shuang Ho Hospital - New Taipei City
Michigan
- Karmanos Cancer Institute - Detroit
- Karmanos Cancer Institute - Farmington Hills
Arkansas
- Highlands Oncology Group - Duplicate 2 - Springdale
California
- Univ of California San Francisco - San Francisco
Colorado
- University of Colorado School of Medicine - Aurora
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Hauts-de-France
- Centre Oscar Lambret - Lille
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2016-11-14 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02779751
The ClinicalTrials.gov registry entry for NCT02779751 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT02779751 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Michigan, Arkansas.
Frequently Asked Questions
What is clinical trial NCT02779751 about?
NCT02779751 is a clinical study titled "A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer". The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.
What is the current status of trial NCT02779751?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2016-11-14. Estimated completion is 2026-12.
What conditions does trial NCT02779751 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02779751?
The interventions under investigation include: Pembrolizumab (DRUG), Anastrozole (DRUG), Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT02779751?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02779751 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.